Home > Cardiology > Ezetimibe, PCSK9 inhibitors recommended to lower MACE risk in some high-risk patients

Ezetimibe, PCSK9 inhibitors recommended to lower MACE risk in some high-risk patients

Journal
The BMJ
Reuters Health - 20/05/2022 -A new guideline recommends adding ezetimibe or PCSK9 inhibitors to reduce the risk of a major adverse cardiovascular event (MACE) in patients at high risk of heart disease on maximum statins or intolerant to statins. The new guideline, issued by a panel of international experts and patients and published in The BMJ, was developed based on a systematic review and meta-analysis of 14 trials involving close to 84,000 patients. The recommendations are for adults who are receiving high doses of or are intolerant to statins with LDL cholesterol levels over 70 mg/dL, and who are considering newer lipid-lowering drugs to reduce cardiovascular risk. Patients are categorized based on their risk of experiencing a MACE within five years: low (<5%); moderate (5%-15%); high (15%-20%); and very high (>20%). "The choice to start these drugs...should be made based on risk of cardiovascular disease, and not on LDL-cholesterol threshold levels...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on